Clinical Trials

RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

RAPT Therapeutics reported the initiation of its first-in-human Phase 1 clinical trial for RPT193, an orally-administered small molecule CCR4 antagonist that is designed to selectively inhibit the migration of type 2 T helper cells, or Th2 cells, into allergically-inflamed tissues.

Talaris Therapeutics initiates phase 3 clinical trial of FCR001 in living donor kidney transplant recipients

Talaris Therapeutics, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, announced the initiation of FREEDOM-1, the company’s Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.

Cyclo Therapeutics completes enrollment in phase 1 trial to evaluate Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, formerly CTD Holdings, a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol Cyclo administered intravenously to Niemann-Pick Disease Type C (NPC) patients.

Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial

Odonate Therapeutics, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the completion of enrollment in CONTESSA, a multinational, multicenter, randomized, Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer.

Horizon Therapeutics initiates PROTECT clinical trial of KRYSTEXXA

Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population.

Boehringer Ingelheim enrolls first patient in Phase II BALANCE-CFTM 1 study

Boehringer Ingelheim announced the first patient enrolled in its Phase II clinical trial BALANCE-CFTM 1 to evaluate a new potential treatment for cystic fibrosis.

Trialbee and TriNetX partner to accelerate patient-centric clinical trials

Trialbee, a world-leading technology provider in patient matching and engagement, is partnering with TriNetX, a leading global real-world health research network comprised of >170M patients across 23 countries to support data-driven digital solutions to accelerate patient-centric clinical trials.

Forbius completes enrollment into phase 1a solid tumour trial of AVID200

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, administered as a monotherapy has fully enrolled.

MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgaris

Roche said that the phase 3 PEMPHIX trial of MabThera (rituximab) in moderate to severe pemphigus vulgaris (PV) met its primary endpoint at Week 52.